• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CHRISTOPH MIETHKE GMBH & CO. KG PROGAV 2.0 SYS W/SA15 A.SPRUNG RESERVOIR; HYDROCEPHALUS MANAGEMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CHRISTOPH MIETHKE GMBH & CO. KG PROGAV 2.0 SYS W/SA15 A.SPRUNG RESERVOIR; HYDROCEPHALUS MANAGEMENT Back to Search Results
Model Number FX426T
Device Problems Material Deformation (2976); Material Integrity Problem (2978)
Patient Problems Failure of Implant (1924); Patient Problem/Medical Problem (2688)
Event Date 10/24/2019
Event Type  Injury  
Manufacturer Narrative
When additional information becomes available, a follow up report will be submitted.
 
Event Description
It was reported that post operatively the shape didn't return to original position.The reporter indicated when the product was pressed for adjustment, the button did not return to the original position.(it remained dented.) however, when the surgeon checked and touched the product several times after revision the button returned to the original position.The event was confirmed when the shunt reconstruction was implemented because of the expose of the tube caused by skin ulcer on the shunt tube running part on the left auricle.Additional details of the event have been requested.
 
Manufacturer Narrative
Additional information: height: 112.5cm.Investigation: visual inspection: in the first step of our investigations, we carried out a visual test on the valve.Permeability test: to proof the penetrability of the shunt system we have carried out penetrability test.This test is carried out at a hydrostatic pressure of approximately 20-30 cmh2o in the direction of flow.Adjustment test: to proof the penetrability of the shunt system we have carried out penetrability test.This test is carried out at a hydrostatic pressure of approximately 20-30 cmh2o in the direction of flow.Braking force and brake function test: to measure the braking force, we tested the progav 2.0 valve with a braking force device.Here it is measured how much force must be exerted on the housing to release the rotor to adjust the valve by the integrated magnet of the braking force device.Results: firstly, we would like to point out that the period between the date of removal ((b)(6) 2019) and investigation (16.01.2020) is very long and that we received the progav 2.0 shunt system dry without liquid.The investigation of a dry shunt system is not meaningful/valuable, since dry deposits of cerebrospinal fluid and blood can impair the product properties.Scratches on the outer casing of the progav 2.0 were observed through the visual inspection.No other significant deformations or damage was detected.Next, we tested the permeability of the valves.Both valves were shown to be non-permeable, indicating blockages.Additionally, we tested the adjustability as well as the brake functionality and brake force of the progav 2.0 valve.The valve operated as expected and met all specifications.Finally, we have dismantled the valves.Inside both valves, we have found slight build-up of substances (likely protein).Based on our investigation, we are confirming the claim of blockage, but a damage of the progav 2.0 housing or adjustment problem we are unable to confirm.The progav 2.0 was adjustable to all settings as specified and the brake function is fully operable.Probably the blockage is due to dry protein deposits in the valves.As described in scientific literature, the problem encountered is one of the known, inevitable risks of hc-therapy by shunt implants.We can exclude a defect at the time of release.The shunt system met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PROGAV 2.0 SYS W/SA15 A.SPRUNG RESERVOIR
Type of Device
HYDROCEPHALUS MANAGEMENT
Manufacturer (Section D)
CHRISTOPH MIETHKE GMBH & CO. KG
2 ulanenweg
potsdam d, 14469
GM  14469
MDR Report Key9353870
MDR Text Key167348308
Report Number3004721439-2019-00291
Device Sequence Number1
Product Code JXG
Combination Product (y/n)N
PMA/PMN Number
K141687
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Type of Report Initial,Followup
Report Date 01/27/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/21/2019
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date07/29/2023
Device Model NumberFX426T
Device Catalogue NumberFX426T
Device Lot Number20038861
Was Device Available for Evaluation? No
Date Manufacturer Received01/17/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age11 YR
Patient Weight23
-
-